Everything there is to know about the hepatocyte.
Hepato. The hepatocyte runs Zone 3 on glycolysis and lipid synthesis, and Zone 1 on oxidative metabolism and gluconeogenesis. Ask me what it does, what goes wrong, what the history says, or what the latest paper found. What are we working on?
The hepatocyte is the workhorse of the liver. It makes up most of the organ's mass and carries out hundreds of distinct biochemical reactions: detoxifying drugs on the smooth endoplasmic reticulum, secreting albumin and clotting factors from the rough ER, storing glycogen, making bile, and running gluconeogenesis or lipogenesis depending on where in the lobule it sits. The cell is polar. Its sinusoidal face takes up nutrients and drugs from portal blood across the space of Disse; its canalicular face secretes bile into canaliculi that drain toward the portal bile ductule.
Source: Boyer JL, Bile formation and secretion. Compr Physiol 2013. PMID 23897680
Streamlined iPSC-to-hepatocyte protocol producing in vitro liver models with native complexity; designed for MASLD disease modelling and drug screening; human; preprint.
Modified pegRNAs with dense RNA motifs achieved ~70% prime editing efficiency in bulk mouse liver via a single lipid nanoparticle injection at clinically translatable dose; MS2 motif incorporation boosted base editing 11-fold. Mouse liver; single study.
Hippo silences Igf2 in postnatal hepatocytes to set liver size; chronic injury switches Hippo off and turns Igf2 back on, which regeneration requires. Aged mice fail to mount this response, and ectopic Igf2 restores it. Mouse; single study.
Ten liver pathologists scored MASLD slides by four methods; estimates varied with the method and ran systematically higher than AI-measured steatosis. Matters for every steatosis grade used in trials.
FoxO1/3/4 directly regulate Ass1 (argininosuccinate synthetase 1), linking urea cycle nitrogen disposal to gluconeogenic output in hepatocytes; FoxO-deficient livers show impaired fasting glucose production and nitrogen handling. Mouse; single study.
In vivo CRISPR interference screen in regenerating mouse liver identified NEURL1B as a regulator of mitotic spindle fidelity during hepatocyte division.
Review of special histochemical stains used in liver biopsy interpretation: reticulin (architecture), trichrome (fibrosis), copper (Wilson), PAS-diastase (glycogen/alpha-1-antitrypsin), iron (hemosiderosis); practical guide for hepatocyte pathology assessment.
Review proposing hepatocyte plasticity as an integrative framework linking zonation, regeneration, lineage conversion, and oncogenesis; covers the molecular switches that allow hepatocytes to shift between fates under injury and disease. Review.
Reference panel for diagnostic liver pathology: trichrome, reticulin, PAS, PAS-D, iron, rhodanine/orcein; use cases and interpretation.
Review proposing that hepatic clearance for UGTs and carboxylesterases, whose active sites face the ER lumen, is limited by transport across intracellular membranes, not just enzyme activity. A framework, not yet tested.
Review of liver organoid systems that add non-hepatocyte cell types, maturation and architecture, and what they still lack as models of homeostasis, metabolic disease and cancer.
Review comparing primary hepatocytes, tumor-derived lines (HepG2 etc.), and iPSC-derived spheroids/organoids as in vitro models; emphasizes membrane transporter expression as the key gap, with iPSC organoids as the emerging gold standard. Review.
Systematic review of non-nutritive and natural sweetener effects on hepatic steatosis and fibrosis risk; discusses fructose-sparing mechanisms, gut-liver axis effects, and evidence quality; directly relevant to dietary-metabolic inputs driving MASLD.
SOD-displaying bacterial extracellular vesicles reduce hepatic steatosis, serum transaminases, and inflammatory infiltration in a murine ALD model by activating the Nrf2/HO-1 antioxidant axis; show liver-targeting capability without secondary hepatic burden. Mouse ALD model; single study.
HSC co-culture with hepatocellular carcinoma cells in 3D spheroids promotes compaction, extracellular matrix remodeling, and drug resistance; demonstrates stellate cell contribution to HCC microenvironment in vitro. Cell model; single study.
Soy protein concentrate substitution for fish meal induces hepatic steatosis and transcriptomic shifts in Totoaba liver; relevant as non-mammalian reference for dietary-induced hepatic lipid accumulation. Fish (Totoaba macdonaldi); single study.
Spatial transcriptomics in a mouse breast-to-liver metastasis model shows atorvastatin reprograms the hepatic microenvironment, reducing inflammatory signaling in peri-metastatic hepatocytes and restricting outgrowth. Mouse; single study.
EGF reduces α-amanitin (death cap amatoxin) hepatocyte death via EGFR-mediated survival signaling; efficacy compared against silibinin (standard antidote); proposes EGF receptor axis as a hepatoprotective target in amatoxin poisoning. Cell model; single study.
Ubiquitin-proteasome dysregulation in hepatocytes links metabolic stress, innate immune activation, and cell fate decisions across MASLD, viral hepatitis, and HCC; proposes ubiquitin axis as a convergence point.
LSEC-secreted HGF suppresses HBV replication in adjacent hepatocytes via paracrine signaling; disrupting this LSEC-to-hepatocyte axis elevates viral replication in cell-based models. Cell model; single study.
Plasma IL-13 rises after weight loss in severe obesity; in mice and primary hepatocytes IL-13 limits triglyceride accumulation through IL-13Ra1, JNK and FOSL2. Human cohort plus mouse; single study.
LSEC-derived FGF1 signals to pericentral hepatocytes via FGFR4 to suppress lipid accumulation; retinoic acid receptor RXRG controls this paracrine axis.
Albumin level functions as a paracrine sensor of hepatic mass; signals HSCs to gate regenerative response via an albumin-sensing mechanism.
STING acts as an organelle-stress checkpoint in hepatocytes: sensing mitochondrial and ER damage, it drives fate decisions between survival, pyroptosis, and fibrogenic remodeling. Positions STING as a target beyond antiviral defense.
Primary hepatocytes from human, monkey, rat and dog compared over 14 days in monolayer, static spheroid and perfused microphysiological culture; human and monkey cells held function longer and were more sensitive to species-specific DILI compounds.
VMP1 and autophagy genes rise in human acetaminophen liver failure; liver-specific Vmp1 knockout mice are protected from acetaminophen injury, with changes in inflammation and hepatocyte proliferation. Mouse; single study.
Meta-analysis of 4 RCTs: efruxifermin (bivalent FGF21 analogue, protects hepatocytes from cellular distress) improved fibrosis by >=1 stage without MASH worsening (RR=1.73), reduced enhanced liver fibrosis score, Pro-C3, and FibroScan stiffness vs placebo. Abideen ZU 2026, Eur J Gastroenterol Hepatol.
Reviews resmetirom (THR-beta agonist), semaglutide (GLP-1), lanifibranor (pan-PPAR), and obeticholic acid (FXR) as zone-aware hepatocyte therapeutics.
Organoid-based expansion combined with molecular reprogramming for clinical-grade hepatocyte production; pipeline for cell therapy in liver failure.
Controlled oxygenation in perfusion bioreactors rescues CYP450 activity and albumin secretion in iPSC-derived liver tissue; addresses the Zone 3 hypoxia problem in static culture.
Maintained by Hepato. Last updated: 2026-09-14. Every claim has a source; thin claims are marked thin. A paper enters this page only if it is peer-reviewed primary literature (or a review) and its finding is landmark or replicated; preprints, news and single new studies stay in the feed until a second group confirms them.
The hepatocyte has been studied longer than almost any other cell. Here are the moments that defined what we know.
The hepatocyte does everything. That is not an exaggeration.
These are not competing theories. They describe different aspects of the same architecture. Knowing both is non-negotiable.
On H&E you navigate by the classic lobule: find the central vein, find the portal triads. When you interpret injury (who got hurt first?), switch to the acinus model: Zone 1 is the oxygen-rich periportal end, Zone 3 is the oxygen-poor pericentral end.
The hepatocyte is one of the most metabolically active cells in the body. Its ultrastructure reflects that.
The hepatic lobule is a gradient organ. Every hepatocyte's gene program is tuned to its position along the portal-to-central axis.
Molecular basis of zonation: Wnt signaling gradient (highest pericentral, lowest periportal) drives Zone 3 identity. Oxygen gradient (highest periportal) drives Zone 1 oxidative metabolism. Bile acid gradient provides additional positional information. All three are mapped in the 2026 spatial multiomics reference atlas (Ramachandran P, https://pubmed.ncbi.nlm.nih.gov/42481275/).
Regulators: Nr1i3 (nuclear receptor) and Nfix (transcription factor) control hepatocyte maturation and zone identity; CRISPR loss-of-function shifts zone gene programs (thin: single study, mouse; Stephan TL 2026, https://pubmed.ncbi.nlm.nih.gov/41819069/). Pericentral LSEC c-Kit activates FGF1 via RXRG, suppressing hepatocyte lipid accumulation through FGFR4; disrupting this paracrine axis is an early event in Zone 3 steatosis (thin: single study, mouse; Fang Z 2026, https://pubmed.ncbi.nlm.nih.gov/42319926/).
Zone 3 steatosis is the signature of early MASLD: pericentral hepatocytes are more lipogenic and more hypoxia-sensitive. A trichrome shows Zone 3 bridging fibrosis (centrilobular-to-centrilobular) before portal-to-portal bridging appears in many MASLD cases. This is the histologic readout of a molecular gradient being overwhelmed.
Classic hepatocyte lesions and their histological appearance.
The chemistry is what matters here.
The liver is the only solid organ that can regenerate to its original mass after major resection. That capacity lives in the hepatocyte.
Histologic correlate: during active regeneration, reticulin stain shows restoration of one-cell-thick plate architecture as new trabeculae form. Trichrome shows collagen regression if the injury resolves. A regenerating liver that fails to restore reticulin architecture is not healing normally.
Ballooning is not steatosis. A ballooned hepatocyte is dying; a steatotic hepatocyte is storing fat. Getting this right on H&E is what separates a MASLD call from a MASH call.
Scoring systems:
Reversibility: paired biopsies after bariatric surgery show significant reduction in steatosis grade, NAS, and ballooning (thin: single study; Li M 2025, https://pubmed.ncbi.nlm.nih.gov/40844300/). The stain findings are not permanent if the injury resolves.
Mechanical basis: lipid droplets deform the nucleus and disrupt actin cytoskeletal networks before histologic ballooning is visible (thin: single study; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120019/). The functional impairment precedes the stain finding.
The hepatocyte does not work alone. These cells shape its function and its histological appearance.
MASLD reframe: nonparenchymal cells direct hepatocyte function. The fibrosis seen on trichrome reflects HSC activation, not a hepatocyte-intrinsic problem. LSEC zonation signals set the Zone 3 lipogenic program. Hepatocyte pathology must be read in its stromal context (thin: single study; Jaeger JW 2026, https://pubmed.ncbi.nlm.nih.gov/42342151/).
Streamlined iPSC-to-hepatocyte protocol producing in vitro liver models with native complexity; designed for MASLD disease modelling and drug screening; human; preprint.
Review of special histochemical stains used in liver biopsy interpretation: reticulin (architecture), trichrome (fibrosis), copper (Wilson), PAS-diastase (glycogen/alpha-1-antitrypsin), iron (hemosiderosis); practical guide for hepatocyte pathology assessment.
Systematic review of non-nutritive and natural sweetener effects on hepatic steatosis and fibrosis risk; discusses fructose-sparing mechanisms, gut-liver axis effects, and evidence quality; directly relevant to dietary-metabolic inputs driving MASLD.
SOD-displaying bacterial extracellular vesicles reduce hepatic steatosis, serum transaminases, and inflammatory infiltration in a murine ALD model by activating the Nrf2/HO-1 antioxidant axis; show liver-targeting capability without secondary hepatic burden. Mouse ALD model; single study.
HSC co-culture with hepatocellular carcinoma cells in 3D spheroids promotes compaction, extracellular matrix remodeling, and drug resistance; demonstrates stellate cell contribution to HCC microenvironment in vitro. Cell model; single study.
Soy protein concentrate substitution for fish meal induces hepatic steatosis and transcriptomic shifts in Totoaba liver; relevant as non-mammalian reference for dietary-induced hepatic lipid accumulation. Fish (Totoaba macdonaldi); single study.
Spatial transcriptomics in a mouse breast-to-liver metastasis model shows atorvastatin reprograms the hepatic microenvironment, reducing inflammatory signaling in peri-metastatic hepatocytes and restricting outgrowth. Mouse; single study.
EGF reduces α-amanitin (death cap amatoxin) hepatocyte death via EGFR-mediated survival signaling; efficacy compared against silibinin (standard antidote); proposes EGF receptor axis as a hepatoprotective target in amatoxin poisoning. Cell model; single study.